Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher

<< Previous

Bullboard Posts

Next >>

Post by nodaytraderon Dec 28, 2021 3:36pm

229 Views

Post# 34265953

Question for Whalewatcher

If I read it right, you are arguing that NASDAQ bases its eligibility criteria on data from CSE.
My question is "why would they do that?"
NASDAQ's trading volume is about US$200 billion a day. CSE's is about CAN$20 million on a good day. So, NASDAQ is 10,000 times bigger.
NASDAQ operates in the US market, which is much bigger than CSE's Canadian market.
Presumably, NASDAQ has the data, experience and knowledge to reach its own conclusions about the value of a company in its own market.
so why would it base its eligibility requirements on data from a relatively tiny exchange, in a much smaller market, that has comparatively little knowledge of the US market?

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?